Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Non-Current Deffered Revenue (2017 - 2024)

Ligand Pharmaceuticals' Non-Current Deffered Revenue history spans 12 years, with the latest figure at $2.2 million for Q4 2024.

  • For Q4 2024, Non-Current Deffered Revenue rose 55.54% year-over-year to $2.2 million; the TTM value through Dec 2024 reached $2.2 million, up 55.54%, while the annual FY2024 figure was $2.2 million, 55.54% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2024 was $2.2 million at Ligand Pharmaceuticals, down from $2.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $9.3 million in Q4 2021 and bottomed at $44000.0 in Q4 2022.
  • The 4-year median for Non-Current Deffered Revenue is $2.7 million (2024), against an average of $3.8 million.
  • The largest annual shift saw Non-Current Deffered Revenue tumbled 99.53% in 2022 before it skyrocketed 3181.82% in 2023.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $9.3 million in 2021, then crashed by 99.53% to $44000.0 in 2022, then surged by 3181.82% to $1.4 million in 2023, then surged by 55.54% to $2.2 million in 2024.
  • Per Business Quant, the three most recent readings for LGND's Non-Current Deffered Revenue are $2.2 million (Q4 2024), $2.5 million (Q3 2024), and $2.7 million (Q2 2024).